Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mycophenolate Mofetil vs Steroids in Alcoholic Hepatitis
NCT06789315Not yet recruiting
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of mycophenolate mofetil in alcoholic hepatitis (AH) (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Short-term survival at 28 days. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
mycophenolate mofetil
03
Conditions
alcoholic hepatitis (AH)
Beyond the preview
Go deeper on NCT06789315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06789315.